new glp-1 drug Drugs from the Gray Market GLP-1 drugs now have new
Description
10.1007/s00125-008-1149-y 21 De MarinisY
Consistent with earlier studies, side effects emerged as the most commonly cited reason for discontinuation, regardless of medication indication
Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al
However, Novo Nordisk has recently developed monoclonal antibodies which, through targeting of the extracellular domain of GLP-1R, allow the detection of GLP-1R in human and rodent tissues with improved selectivity [[392], [393], [394]]
